Literature DB >> 22162573

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.

Andrew S Chi1, Tracy T Batchelor, Eunice L Kwak, Jeffrey W Clark, Daphne L Wang, Keith D Wilner, David N Louis, A John Iafrate.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22162573     DOI： 10.1200/JCO.2011.38.4586

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  38 in total

1.  Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Authors:  Hartmut Koeppen; Wei Yu; Jiping Zha; Ajay Pandita; Elicia Penuel; Linda Rangell; Rajiv Raja; Sankar Mohan; Rajesh Patel; Rupal Desai; Ling Fu; An Do; Vaishali Parab; Xiaoling Xia; Tom Januario; Sharianne G Louie; Ellen Filvaroff; David S Shames; Ignacio Wistuba; Marina Lipkind; Jenny Huang; Mirella Lazarov; Vanitha Ramakrishnan; Lukas Amler; See-Chun Phan; Premal Patel; Amy Peterson; Robert L Yauch
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

Review 2.  Toward precision medicine in glioblastoma: the promise and the challenges.

Authors:  Michael D Prados; Sara A Byron; Nhan L Tran; Joanna J Phillips; Annette M Molinaro; Keith L Ligon; Patrick Y Wen; John G Kuhn; Ingo K Mellinghoff; John F de Groot; Howard Colman; Timothy F Cloughesy; Susan M Chang; Timothy C Ryken; Waibhav D Tembe; Jeffrey A Kiefer; Michael E Berens; David W Craig; John D Carpten; Jeffrey M Trent
Journal:  Neuro Oncol       Date:  2015-05-01       Impact factor: 12.300

3.  Promise and challenges on the horizon of MET-targeted cancer therapeutics.

Authors:  Yu-Wen Zhang
Journal:  World J Biol Chem       Date:  2015-05-26

4.  Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Authors:  Simona Cignetto; Chiara Modica; Cristina Chiriaco; Lara Fontani; Paola Milla; Paolo Michieli; Paolo M Comoglio; Elisa Vigna
Journal:  Mol Oncol       Date:  2016-03-28       Impact factor: 6.603

5.  MET signaling promotes DNA repair and radiation resistance in glioblastoma stem-like cells.

Authors:  Pavlina Krasimirova Todorova; Bipasha Mukherjee; Sandeep Burma
Journal:  Ann Transl Med       Date:  2017-02

Review 6.  Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.

Authors:  Gerald C Wallace; Yaenette N Dixon-Mah; W Alex Vandergrift; Swapan K Ray; Catherine P Haar; Amber M Mittendorf; Sunil J Patel; Naren L Banik; Pierre Giglio; Arabinda Das
Journal:  Metab Brain Dis       Date:  2013-04-02       Impact factor: 3.584

Review 7.  MET overexpression and gene amplification in NSCLC: a clinical perspective.

Authors:  Lorenza Landi; Gabriele Minuti; Armida D'Incecco; Jessica Salvini; Federico Cappuzzo
Journal:  Lung Cancer (Auckl)       Date:  2013-06-18

8.  Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.

Authors:  Alberto Broniscer; Sujuan Jia; Belinda Mandrell; Dima Hamideh; Jie Huang; Arzu Onar-Thomas; Amar Gajjar; Susana C Raimondi; Ruth G Tatevossian; Clinton F Stewart
Journal:  Pediatr Blood Cancer       Date:  2018-03-07       Impact factor: 3.167

Review 9.  Glioblastoma targeted therapy: updated approaches from recent biological insights.

Authors:  M Touat; A Idbaih; M Sanson; K L Ligon
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

10.  Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.

Authors:  Emilie Le Rhun; Marc C Chamberlain; Fahed Zairi; Christine Delmaire; Ahmed Idbaih; Florence Renaud; Claude Alain Maurage; Valérie Grégoire
Journal:  CNS Oncol       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.